Anjali Singh

Biocon expects momentum to strengthen in H2FY27, driven by new US biosimilar and generic launches, improved operating leverage and a favourable product mix

Emcure expects overseas markets to drive growth in FY27 through product approvals, differentiated offerings and capacity expansion, while domestic business is seen improving

The disease-modifying therapy for early Alzheimer's disease will cost ₹21,682 per vial, with treatment expenses varying according to patients' weight and dosage

Industry body says it is open to a shorter regulatory data protection period if the clock starts from a drug's marketing approval in India rather than its first global approval

Sun Pharma reported a 27 per cent rise in Q1FY27 profit, driven by India and innovative medicines, while weakness in the US generics business continued to weigh on growth

Higher capacity utilisation, operating leverage and broad-based demand across CDMO, hospital generics and consumer healthcare are expected to support margins in FY27

Mahindra Group chairman says prolonged global uncertainty offers prepared companies an edge, with India poised to emerge as a multi-aligned 'connector economy'

The private equity firm has taken control of the BSE-listed drugmaker, appointed Vikas Gupta as CEO and plans to build a branded generics platform in India

Sun Pharma will launch the once-weekly diabetes treatment through Hypera Pharma as generic competition intensifies in Brazil's $413 million semaglutide market

Engineering major will invest over five years in EV motors, ADAS and connected-vehicle technologies, targeting a fast-growing market dominated by global players

The company retailed 1,665 vehicles in Q1 FY27, up 11 per cent year-on-year, with the Range Rover, Range Rover Sport and Defender accounting for over 85 per cent of sales

Flooding in Gujarat disrupts operations at Tata Motors' Sanand plant and supplier facilities, with production of key passenger vehicle models affected

Forging company reports a 298 per cent jump in quarterly profit on higher revenue and margins, while approving ₹170 crore capex to expand passenger vehicle components business

Hero, TVS, and Bajaj count on overseas markets while bracing for global uncertainty

₹9,275-crore issue opens on July 29 as the Temasek-backed hospital chain plans to add around 3,000 beds through greenfield and brownfield projects

The drugmaker attributed the decline to a high base in North America, retained its FY27 Ebitda margin guidance and expects new product launches to support growth

The luxury carmaker expects 2026 to be its best-ever year, supported by robust order books, sustained demand across segments and strong festive-season momentum

The drugmaker attributed the sharp earnings decline to a one-time semaglutide provision and the end of its lenalidomide agreement, while retaining its FY27 guidance

Chairman Sudarshan Venu says overseas operations now contribute over a quarter of revenue as the company expands across Africa, Latin America, Asia and Europe

Revenue rose 34 per cent as TVS Motor posted record quarterly sales, with management expecting double-digit industry growth to continue on strong exports and EV demand